14 completed, 2 terminated, 2 withdrawn, 1 unknown. 19 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 14, Terminated 2, Withdrawn 2, Unknown 1 |
| Phase 2 | 9 | Completed 9 |
Follow Phobic Disorders: new trials by email Literature Review of Phobic Disorders trials Research Report on Phobic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Arthritis Ease Study Virtual Reality Nature scene plus heart rate variability biofeedback phone application - Knee Osteoarthritis, Chronic Pain | Phase 1 / Phase 2 | Completed | Arizona State University | 36 | 2022-09-15 | 2024-09-23 |
| A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline Propranolol, Prazosin - Post-traumatic Stress Disorder (PTSD) | Phase 1 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 34 | 2022-09-07 | 2024-01-23 |
| Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD) Low dose RLS103, High dose RLS103, placebo inhaled dry powder - Social Anxiety Disorder | Phase 1 | Withdrawn | Receptor Life Sciences | 2022-05-18 | 2024-04-02 | |
| Adaptive Treatment Strategies for Improving Engagement With a Web-Based Smoking Intervention in Socially Anxious Smokers Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages, Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages, Phase 2: re-engagement text messages - Social Anxiety Disorder, Tobacco Use Disorder | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2022-04-15 | 2021-12-08 | |
| Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers Paroxetine Hydrochloride Tablet 20 mg, Paxil® 20 mg - Major Depressive Disorder, Obsessive-Compulsive Disorder | Phase 1 | Completed | Beijing Tongren Hospital | 53 | 2018-03-29 | 2018-12-19 |
| Intelligent Virtual Reality Therapy System and Testing Its Clinical Efficacy Intelligent Virtual Reality Therapy System (IVRTS) - Phobias, Acrophobia | Phase 1 / Phase 2 | Completed | University College of Medical Sciences, India | 500 | 2018-02-05 | 2020-11-09 |
| The Modular Protocol for Mental Health (MPMH) The Modular Protocol for Mental Health, Treatment-as-usual - Major Depressive Disorder, Generalized Anxiety Disorder | Phase 1 / Phase 2 | Completed | Medical Research Council Cognition and Brain Sciences Unit | 43 | 2017-07-18 | 2020-09-29 |
| Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy - Phobias, Claustrophobia | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 112 | 2015-08-01 | 2022-12-28 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| Generalization of Extinction Learning Scopolamine, intranasal placebo - Social Anxiety Disorder | Phase 1 | Completed | University of California, Los Angeles | 60 | 2013-08-01 | 2019-10-07 |
| Bringing What Works to Youth in Corrections: A Trauma Intervention Trauma-Focused Cognitive Behavioral Therapy - Post-Traumatic Stress Disorder | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 57 | 2012-11-01 | 2016-03-17 |
| Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder Oxytocin, Placebo - Social Anxiety Disorder | Phase 1 / Phase 2 | Completed | Stefan G. Hofmann | 60 | 2012-07-01 | 2018-02-13 |
| Treatment Study for Rural Latino Youth With Anxiety Therapist-Assisted by Telephone, Self-Help - Anxiety Disorders, Separation Anxiety Disorder | Phase 1 / Phase 2 | Completed | University of California, San Diego | 43 | 2011-11-01 | 2019-08-15 |
| Cipralex® for Anxiety Disorders in Adolescents Cipralex® - Anxiety Disorder | Phase 1 | Unknown | University of Ottawa | 30 | 2008-03-01 | 2011-02-11 |
| A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills GW876008, COC - Social Phobia | Phase 1 | Terminated | GlaxoSmithKline | 4 | 2007-06-08 | 2017-08-04 |
| A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder GSK561679 tablet, GW876008 tablet, alprazolam - Social Phobia | Phase 1 | Completed | GlaxoSmithKline | 35 | 2007-03-27 | 2017-08-04 |
| A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder Placebo treatment during 8 weeks, Paroxetine treatment during 8 weeks - Social Phobia | Phase 1 | Completed | GlaxoSmithKline | 56 | 2007-01-22 | 2017-07-18 |
| fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder GW679769 - Social Anxiety Disorder | Phase 1 | Completed | GlaxoSmithKline | 57 | 2006-01-01 | 2008-10-16 |
| Treatment for Specific Phobias in Children One-Session Treatment for Specific Phobias - Phobic Disorders, Anxiety Disorders | Phase 1 / Phase 2 | Completed | Virginia Polytechnic Institute and State University | 150 | 2001-10-01 | 2013-06-07 |
Phobia, Social (16) · Generalized Anxiety Disorder (7) · Anxiety Disorders (6) · Panic Disorder (5) · Depressive Disorder, Major (4) · Obsessive-Compulsive Disorder (4) · Anxiety, Separation (3) · Stress Disorders, Post-Traumatic (3) · Phobia, Specific (2) · Acrophobia (1) · Agoraphobia (1) · Chronic Pain (1) · Claustrophobia (1) · Depression (1)
Mental Disorders (18) · Anxiety Disorders (13) · Depressive Disorder (4) · Mood Disorders (4) · Neurodevelopmental Disorders (3) · Stress Disorders, Traumatic (3) · Trauma and Stressor Related Disorders (3) · Behavior (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Arthritis (1) · Behavioral Symptoms (1) · Chemically-Induced Disorders (1)
GW 876008 (2) · Alprazolam (1) · Dexetimide (1) · Implosive Therapy (1) · Low-Level Light Therapy (1) · Mental Health (1) · NBI 77860 (1) · Oxytocin (1) · Paroxetine (1) · Prazosin (1) · Propranolol (1) · Scopolamine (1) · Therapeutics (1) · casopitant (1)
GlaxoSmithKline (4) · University of Texas at Austin (2) · Arizona State University (1) · Beijing Tongren Hospital (1) · Fred Hutchinson Cancer Center (1) · Medical Research Council Cognition and Brain Sciences Unit (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Receptor Life Sciences (1) · Stefan G. Hofmann (1) · University College of Medical Sciences, India (1) · University of California, Los Angeles (1) · University of California, San Diego (1) · University of Ottawa (1) · University of South Florida (1) · Virginia Polytechnic Institute and State University (1)
United States (12) · Spain (2) · United Kingdom (2) · Canada (1) · China (1) · India (1) · Sweden (1)
Denise A Chavira, PhD (1) · Linda Larkey, PhD (1) · Manjit Singh Bhatia, MBBS; MD (1) · Martine Flament, MD (1) · Michael Fanselow, Ph.D. (1) · Michael J. Telch, Ph.D. (1) · Michelle G. Craske, Ph.D. (1) · Molly M Lopez, Ph.D. (1) · Noreen Watson (1) · Tim Dalgleish, PhD (1) · Xiuli Zhao, PhD (1)
PMID 12296495, PMID 20235773, PMID 21492829, PMID 21639653, PMID 23398031, PMID 26203478, PMID 26833396, PMID 28475502, PMID 28559206, PMID 29792485, PMID 30007519, PMID 30082367, PMID 30696471, PMID 31174846, PMID 34284836
K23DA048181 (1), R01MH059308 (1), R34MH090149 (1), R34MH095210 (1)